Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Just spent some time digging into healthcare ETFs and honestly, there's way more variety than I expected. If you're thinking about getting exposure to pharma without picking individual stocks, these funds are pretty solid—lower volatility than holding single companies, plus you get that diversification thing working for you. I found that the bigger healthcare ETF plays have AUM ranging from like 86 million to 1.2 billion, so plenty of options depending on your portfolio size. Expense ratios are mostly under 0.65 percent, which is reasonable. The VanEck Pharma ETF (PPH) seems to be the heavyweight with 1.2 billion in assets and a 0.36 percent fee. Top holdings across most of these are the usual suspects—Eli Lilly, Merck, Johnson & Johnson—so you're basically getting a basket of blue-chip pharma plays. There's also the China-focused healthcare ETF if you want international exposure, though it's smaller. Noticed that a lot of these healthcare ETF options started hitting the market back in 2005-2006, so they've been around long enough to have solid track records. The holdings vary though—some lean heavy on oncology and biotech, others are more diversified across pain management and vaccines. Worth looking at if you want sector exposure without the stock-picking headache.